Nordic Life Science
Pharma
Latest Pharma News
The company will receive a milestone payment from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD)
The biotech company has announced the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from
After discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a
Nexstim’s business partner PO Medica AB has sold two Navigated Brain Therapy (NBT) systems to two different hospitals Sweden. Both hospitals will be the first in Sweden to have the
The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control
Clinical trials
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute
The company has completed patient enrollment in the phase Ib/II trial of ONCOS-102 in combination with chemotherapy in unresectable malignant
The company has announced positive results from their Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic
The company has completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa.
The topline results from the 12-month follow-up review of the Phase 1 Lymfactin trial in breast cancer-associated lymphedema has been
The Permanent Secretary at Ministry of Health Dr Kennedy Malama together with the Swedish Ambassador Henrik Cederin, Dr Izukanji Sikazwe
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal
A Phase II trial has demonstrated that Fasenra (benralizumab) can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome
The company has initiated a novel TLR9 agonist project and announces a plan for a Phase I clinical trial. Clinical
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and
The last patient has been enrolled in the company’s study for the localized treatment of prostate cancer. The Phase IIb
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments